Today's Research Report Coverage on Medical Equipment Stocks -- Neovasc, NuVasive, Amedica, and Accuray

Tuesday, June 13, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 13, 2017 /PRNewswire/ --

Today's research on is focused on the Medical Appliances

and Equipment space, which includes companies that are engage in the manufacture of medical instruments such as dental and surgical appliances. Lined up for review this morning are: Neovasc Inc. (NASDAQ: NVCN), NuVasive Inc. (NASDAQ: NUVA), Amedica Corp.
(NASDAQ: AMDA), and Accuray Inc. (NASDAQ: ARAY). Learn more about these stocks by signing up for their free reports on at:


On Monday, shares in Richmond, Canada headquartered Neovasc Inc. recorded a trading volume of 62,085 shares. The stock ended the session 2.00% lower at $1.47. The Company's shares have gained 4.26% in the last one month and 5.00% over the previous three months. The stock is trading 20.05% above its 200-day moving average. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have a Relative Strength Index (RSI) of 44.50. The free research report on NVCN is available at:


San Diego, California headquartered NuVasive Inc.'s stock closed the day 1.74% lower at $77.75. A total volume of 973,752 shares was traded, which was above their three months average volume of 615,120 shares. The Company's shares have advanced 9.12% in the past month, 4.29% in the previous three months, and 15.42% since the start of this year. The stock is trading 5.18% and 11.97% above its 50-day and 200-day moving averages, respectively. Additionally, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 61.11.

On June 05th, 2017, NuVasive announced the PRECICE® system and PRECICE UNYTE™ platform from NuVasive Specialized Orthopedics are featured in the June 2017 supplement of the Journal of Orthopaedic Trauma, which demonstrates a lower complication rate, greater patient comfort, and faster healing in comparison to traditional treatments.

On June 06th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $76 a share to $85 a share. The complimentary report on NUVA can be downloaded at:


Shares in Salt Lake City, Utah headquartered Amedica Corp. recorded a trading volume of 1.14 million shares, which was higher than their three months average volume of 560,550 shares. The stock ended yesterday's trading session 1.47% lower at $0.34. The Company's shares are trading below their 50-day moving average by 7.51%. Furthermore, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have an RSI of 51.49.

On June 08th, 2017, Amedica announced its preliminary earnings report for Q4 and fiscal year ended December 31st, 2016. For Q4 2016, the Company reported preliminary revenue of $3.6 million and GAAP net loss of $0.16 per share. For the full year, revenue was $15.2 million and GAAP net loss was $1.19 per share. Additionally, cash and cash equivalents were $6.9 million at December 31st, 2016. Visit us today and download our complete research report on AMDA for free at:


Sunnyvale, California headquartered Accuray Inc.'s stock finished Monday's session 5.75% lower at $4.10 with a total trading volume of 813,799 shares. The Company's shares are trading below their 50-day moving average by 6.56%. Shares of the company, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 42.91.

On May 24th, 2017, Accuray announced that it has appointed, Stan Gee, who has been with the Company for over eight years, to the newly created Vice President of Revenue Management position reporting to Kevin Waters, CFO. Mr. Gee will be responsible for driving the global revenue forecast and overseeing the order to revenue conversion process for the Company. Get free access to your technical report on ARAY at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store